The CATERPILLAR study
The CATERPILLAR study:
The efficacy of TauroLock-Hep100 for the prevention of tunnelled central line-associated bloodstream infections in pediatric oncology patients
The efficacy of TauroLock-Hep100 for the prevention of tunnelled central line-associated bloodstream infections in pediatric oncology patients
Background
Tunneled central venous access devices (CVAD) are fundamental in pediatric oncology for long-term venous access. The rate of central line-associated bloodstream infections (CLABSI) in this patient group is high, which results in high morbidity. CLABSIs are seen in at least 30% of the children with a CVAD, 17% of the inserted CVADs are removed early and 5% of the patients are admitted at an intensive care unit due to CLABSIs. In literature, TauroLock-Hep100 is suggested as the most promising and safe method for the prevention of CLABSIs. TauroLock-Hep100 has anticoagulant and antimicrobial properties without reported microbial resistance. Currently, in the standard of care of pediatric oncology patients in the Netherlands, the heparin lock is used, which only has anticoagulant properties. An open labelled randomized controlled trial will be performed to study efficacy and safety of TauroLock-Hep100 in pediatric oncology patients for the prevention of CLABSIs.
Aims
Aims
The aim of this study is to increase quality of life for children with cancer by reducing the CLABSI-rate, CVAD-removal rate, dispense of antibiotics, days of hospital/intensive care unit admission, and morbidity/mortality rate due to CLABSI.
Project Outcomes
Project Outcomes
van den Bosch CH, van der Bruggen JT, Frakking FNJ, Terwisscha van Scheltinga CEJ, van de Ven CP, van Grotel M, Wellens LM, Loeffen YGT, Fiocco M, Wijnen MHWA (2019). Incidence, severity and outcome of central line related complications in pediatric oncology patients: A single center study. J Pediatr Surg, 54(9):1894-1900. doi: 10.1016/j.jpedsurg.2018.10.054.
Team
Team
Drs. C. van den Bosh, PhD candidate at the Princess Maxima Center for Pediatric Oncology
Prof. dr. M. Fiocco, Mathematical Institute Leiden University, Department of Biomedical Data Sciences Leiden University Medical Center & Princess Máxima Center for Pediatric Oncology
Drs. C.P. van de Ven, Pediatric Surgeon at the Princess Maxima Center for Pediatric Oncology
Dr. M.D. van de Wetering, Pediatric Oncologist at the Princess Maxima Center for Pediatric Oncology
Prof. dr. M.H.W.A. Wijnen, Pediatric Surgeon at the Princess Maxima Center for Pediatric Oncology
